← Human Trials & Peer-Reviewed Studies
Impact of Dentin Pretreatment With Dimethyl Sulfoxide on Behavior of Resin Composite Restorations in Non-Carious Cervical Lesions
Plain-language guide to NCT07830641: not phased randomized trial of DMSO (dimethyl sulfoxide, non-peptide solvent), 30 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT07830641
- Phase
- not phased
- Status
- completed
- Start
- 2023-12-15
- Completion (planned or actual)
- 2025-12-15
- Participants
- 30 (actual)
- Design
- randomized, double-blind, treatment
- Conditions studied
- Class V Non-carious Cervical Dental Lesions
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
The trial (not phased) is built around DMSO (dimethyl sulfoxide, non-peptide solvent).
The aim of this study to evaluate and compare the impact of dimethyl sulfoxide dentin surface pretreatment on the performance of composite restorations in non-cervical carious lesions.
It had two arms (groups): one (experimental) and one (experimental).
Participants in this group will receive resin composite restorations using etch-and-rinse adhesive system under conventional wet-bonding without DMSO solution treatment . after acid aching, the dentin will be maintained in a visibility moist condition . the assigned adhesive system and resin composite material will be applied and polymerized in accordance with the standardized clinical protocol.
The registry classes the interventions as other.
Who Took Part
30 actual participants took part.
It was open to people of any sex aged from 18 years up to 60 years.
Healthy volunteers could join, not only people with the condition.
Examples of who could join: The cervical cavity margin had to be equigingival or supragingival. Participants had to be willing and able to comply with the study protocol and attend all scheduled follow-up visits.
The full record lists 8 inclusion and 1 exclusion criteria.
How the Study Was Run
It was run as a randomized, crossover and double-blind study.
Random assignment meant chance, not the researchers, decided who got DMSO (dimethyl sulfoxide, non-peptide solvent) and who got the comparison, which limits bias.
Each person switched between DMSO (dimethyl sulfoxide, non-peptide solvent) and the comparison at some point, usually with a gap in between.
Blinding on both sides kept the participants and researchers unaware of who received DMSO (dimethyl sulfoxide, non-peptide solvent).
Those kept unaware of assignments: participant and investigator.
It started in 2023-12-15 with completion listed for 2025-12-15.
It ran at 1 site in Egypt.
Its stated primary purpose is treatment.
What Was Measured
Researchers chose this as the main measure: 1. FDI criteria score-aesthetic properties (A1 surface luster and surface texture; A2 Marginal staining; A3 color match), Functional (F1 Fracture/Retention; F2 marginal adaptation), biological (B1 caries at restoration margin) (time frame: Post-restoration baseline (2 weeks), 6, 12, 18, and 24 months). FDI criteria score (time frame: Post-restoration baseline (2 weeks), 6, 12, 18, and 24 months).
What This Means in Plain Language
Put simply, this is a not phased, randomized trial of DMSO (dimethyl sulfoxide, non-peptide solvent) in 30 people.
Its size is small, so on its own it can only give an early look.
The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the DMSO (dimethyl sulfoxide, non-peptide solvent) compound page, all human trials.
Our Notes on the Compound
DMSO (dimethyl sulfoxide, non-peptide solvent): A solvent that carries substances through skin and into the blood, described as a free-radical scavenger; not a peptide.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.